Thin
1 / 2
Survodutide is a peptide compound designed as a GLP-1/GIP/glucagon multi-receptor agonist under clinical investigation for potential benefits in metabolic regulation, weight management, and glucose control. It is being evaluated in clinical studies for its unique balanced receptor agonism profile.
Unlike some established peptide drugs with long-standing granted patents, Survodutide’s patent landscape is still evolving. Careful review of publicly available patent databases reveals pending patent applications related to multi-agonist peptide compositions and methods of use, but no single fully granted, composition-of-matter patent for Survodutide with a confirmed expiration date is currently available in the public domain.
Survodutide is an investigational peptide compound functioning as a GLP-1/GIP/glucagon multi-receptor agonist. It is clinically investigated for balanced receptor agonism to support metabolic regulation, glucose control, and weight management.
In human Phase 2 and Phase 3 clinical studies, Survodutide is administered via once-weekly subcutaneous injections.
Investigational doses typically evaluated include 2 mg, 4 mg, 6 mg, and 8 mg per week, featuring structured dose escalation guided by clinical endpoints and tolerability.
Dose escalation protocols are structured systematically and adjusted according to individual participant tolerability and predefined clinical endpoints.
No. Survodutide dosages and regimens are strictly intended for research purposes and must only be administered within authorized clinical trial protocols.
The patent landscape for Survodutide is currently evolving with pending patent applications for multi-agonist peptide compositions. No single fully granted composition-of-matter patent with a confirmed expiration date is present in the public domain.
